Cargando…

A Five Year Randomized Controlled Trial to Assess the Efficacy and Antibody Responses to a Commercial and Autogenous Vaccine for the Prevention of Infectious Bovine Keratoconjunctivitis

A randomized control trial was performed over a five-year period to assess the efficacy and antibody response induced by autogenous and commercial vaccine formulations against infectious bovine keratoconjunctivitis (IBK). Calves were randomly assigned each year to one of three arms: an autogenous va...

Descripción completa

Detalles Bibliográficos
Autores principales: Hille, Matthew M., Spangler, Matthew L., Clawson, Michael L., Heath, Kelly D., Vu, Hiep L. X., Rogers, Rachel E. S., Loy, John Dustin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228096/
https://www.ncbi.nlm.nih.gov/pubmed/35746524
http://dx.doi.org/10.3390/vaccines10060916
_version_ 1784734350420475904
author Hille, Matthew M.
Spangler, Matthew L.
Clawson, Michael L.
Heath, Kelly D.
Vu, Hiep L. X.
Rogers, Rachel E. S.
Loy, John Dustin
author_facet Hille, Matthew M.
Spangler, Matthew L.
Clawson, Michael L.
Heath, Kelly D.
Vu, Hiep L. X.
Rogers, Rachel E. S.
Loy, John Dustin
author_sort Hille, Matthew M.
collection PubMed
description A randomized control trial was performed over a five-year period to assess the efficacy and antibody response induced by autogenous and commercial vaccine formulations against infectious bovine keratoconjunctivitis (IBK). Calves were randomly assigned each year to one of three arms: an autogenous vaccine treatment that included Moraxella bovis (M. bovis), Moraxella bovoculi, and Mycoplasma bovoculi antigens, a commercial M. bovis vaccine treatment, or a sham vaccine treatment that consisted only of adjuvant. A total of 1198 calves were enrolled in the study. Calves were administered the respective vaccines approximately 21 days apart, just prior to turnout on summer pastures. Treatment effects were analyzed for IBK incidence, retreatment incidence, 205-day adjusted weaning weights, and antibody response to the type IV pilus protein (pili) of M. bovis as measured by a novel indirect enzyme-linked immunosorbent screening assay (ELISA). Calves vaccinated with the autogenous formulation experienced a decreased cumulative incidence of IBK over the entire study compared to those vaccinated with the commercial and sham formulations (24.5% vs. 30.06% vs. 30.3%, respectively, p = 0.25), and had less IBK cases that required retreatment compared to the commercial and sham formulations (21.4% vs. 27.9% vs. 34.3%, respectively, p = 0.15), but these differences were not significant. The autogenous formulation induced a significantly stronger antibody response than the commercial (p = 0.022) and sham formulations (p = 0.001), but antibody levels were not significantly correlated with IBK protection (p = 0.37).
format Online
Article
Text
id pubmed-9228096
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92280962022-06-25 A Five Year Randomized Controlled Trial to Assess the Efficacy and Antibody Responses to a Commercial and Autogenous Vaccine for the Prevention of Infectious Bovine Keratoconjunctivitis Hille, Matthew M. Spangler, Matthew L. Clawson, Michael L. Heath, Kelly D. Vu, Hiep L. X. Rogers, Rachel E. S. Loy, John Dustin Vaccines (Basel) Article A randomized control trial was performed over a five-year period to assess the efficacy and antibody response induced by autogenous and commercial vaccine formulations against infectious bovine keratoconjunctivitis (IBK). Calves were randomly assigned each year to one of three arms: an autogenous vaccine treatment that included Moraxella bovis (M. bovis), Moraxella bovoculi, and Mycoplasma bovoculi antigens, a commercial M. bovis vaccine treatment, or a sham vaccine treatment that consisted only of adjuvant. A total of 1198 calves were enrolled in the study. Calves were administered the respective vaccines approximately 21 days apart, just prior to turnout on summer pastures. Treatment effects were analyzed for IBK incidence, retreatment incidence, 205-day adjusted weaning weights, and antibody response to the type IV pilus protein (pili) of M. bovis as measured by a novel indirect enzyme-linked immunosorbent screening assay (ELISA). Calves vaccinated with the autogenous formulation experienced a decreased cumulative incidence of IBK over the entire study compared to those vaccinated with the commercial and sham formulations (24.5% vs. 30.06% vs. 30.3%, respectively, p = 0.25), and had less IBK cases that required retreatment compared to the commercial and sham formulations (21.4% vs. 27.9% vs. 34.3%, respectively, p = 0.15), but these differences were not significant. The autogenous formulation induced a significantly stronger antibody response than the commercial (p = 0.022) and sham formulations (p = 0.001), but antibody levels were not significantly correlated with IBK protection (p = 0.37). MDPI 2022-06-09 /pmc/articles/PMC9228096/ /pubmed/35746524 http://dx.doi.org/10.3390/vaccines10060916 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hille, Matthew M.
Spangler, Matthew L.
Clawson, Michael L.
Heath, Kelly D.
Vu, Hiep L. X.
Rogers, Rachel E. S.
Loy, John Dustin
A Five Year Randomized Controlled Trial to Assess the Efficacy and Antibody Responses to a Commercial and Autogenous Vaccine for the Prevention of Infectious Bovine Keratoconjunctivitis
title A Five Year Randomized Controlled Trial to Assess the Efficacy and Antibody Responses to a Commercial and Autogenous Vaccine for the Prevention of Infectious Bovine Keratoconjunctivitis
title_full A Five Year Randomized Controlled Trial to Assess the Efficacy and Antibody Responses to a Commercial and Autogenous Vaccine for the Prevention of Infectious Bovine Keratoconjunctivitis
title_fullStr A Five Year Randomized Controlled Trial to Assess the Efficacy and Antibody Responses to a Commercial and Autogenous Vaccine for the Prevention of Infectious Bovine Keratoconjunctivitis
title_full_unstemmed A Five Year Randomized Controlled Trial to Assess the Efficacy and Antibody Responses to a Commercial and Autogenous Vaccine for the Prevention of Infectious Bovine Keratoconjunctivitis
title_short A Five Year Randomized Controlled Trial to Assess the Efficacy and Antibody Responses to a Commercial and Autogenous Vaccine for the Prevention of Infectious Bovine Keratoconjunctivitis
title_sort five year randomized controlled trial to assess the efficacy and antibody responses to a commercial and autogenous vaccine for the prevention of infectious bovine keratoconjunctivitis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228096/
https://www.ncbi.nlm.nih.gov/pubmed/35746524
http://dx.doi.org/10.3390/vaccines10060916
work_keys_str_mv AT hillematthewm afiveyearrandomizedcontrolledtrialtoassesstheefficacyandantibodyresponsestoacommercialandautogenousvaccineforthepreventionofinfectiousbovinekeratoconjunctivitis
AT spanglermatthewl afiveyearrandomizedcontrolledtrialtoassesstheefficacyandantibodyresponsestoacommercialandautogenousvaccineforthepreventionofinfectiousbovinekeratoconjunctivitis
AT clawsonmichaell afiveyearrandomizedcontrolledtrialtoassesstheefficacyandantibodyresponsestoacommercialandautogenousvaccineforthepreventionofinfectiousbovinekeratoconjunctivitis
AT heathkellyd afiveyearrandomizedcontrolledtrialtoassesstheefficacyandantibodyresponsestoacommercialandautogenousvaccineforthepreventionofinfectiousbovinekeratoconjunctivitis
AT vuhieplx afiveyearrandomizedcontrolledtrialtoassesstheefficacyandantibodyresponsestoacommercialandautogenousvaccineforthepreventionofinfectiousbovinekeratoconjunctivitis
AT rogersracheles afiveyearrandomizedcontrolledtrialtoassesstheefficacyandantibodyresponsestoacommercialandautogenousvaccineforthepreventionofinfectiousbovinekeratoconjunctivitis
AT loyjohndustin afiveyearrandomizedcontrolledtrialtoassesstheefficacyandantibodyresponsestoacommercialandautogenousvaccineforthepreventionofinfectiousbovinekeratoconjunctivitis
AT hillematthewm fiveyearrandomizedcontrolledtrialtoassesstheefficacyandantibodyresponsestoacommercialandautogenousvaccineforthepreventionofinfectiousbovinekeratoconjunctivitis
AT spanglermatthewl fiveyearrandomizedcontrolledtrialtoassesstheefficacyandantibodyresponsestoacommercialandautogenousvaccineforthepreventionofinfectiousbovinekeratoconjunctivitis
AT clawsonmichaell fiveyearrandomizedcontrolledtrialtoassesstheefficacyandantibodyresponsestoacommercialandautogenousvaccineforthepreventionofinfectiousbovinekeratoconjunctivitis
AT heathkellyd fiveyearrandomizedcontrolledtrialtoassesstheefficacyandantibodyresponsestoacommercialandautogenousvaccineforthepreventionofinfectiousbovinekeratoconjunctivitis
AT vuhieplx fiveyearrandomizedcontrolledtrialtoassesstheefficacyandantibodyresponsestoacommercialandautogenousvaccineforthepreventionofinfectiousbovinekeratoconjunctivitis
AT rogersracheles fiveyearrandomizedcontrolledtrialtoassesstheefficacyandantibodyresponsestoacommercialandautogenousvaccineforthepreventionofinfectiousbovinekeratoconjunctivitis
AT loyjohndustin fiveyearrandomizedcontrolledtrialtoassesstheefficacyandantibodyresponsestoacommercialandautogenousvaccineforthepreventionofinfectiousbovinekeratoconjunctivitis